RU2020103424A3 - - Google Patents

Download PDF

Info

Publication number
RU2020103424A3
RU2020103424A3 RU2020103424A RU2020103424A RU2020103424A3 RU 2020103424 A3 RU2020103424 A3 RU 2020103424A3 RU 2020103424 A RU2020103424 A RU 2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A RU 2020103424 A3 RU2020103424 A3 RU 2020103424A3
Authority
RU
Russia
Application number
RU2020103424A
Other languages
Russian (ru)
Other versions
RU2020103424A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020103424A publication Critical patent/RU2020103424A/ru
Publication of RU2020103424A3 publication Critical patent/RU2020103424A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2020103424A 2017-06-29 2018-06-29 Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения RU2020103424A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762526377P 2017-06-29 2017-06-29
US62/526377 2017-06-29
PCT/EP2018/067523 WO2019002532A1 (en) 2017-06-29 2018-06-29 21-DAY FUSION PROTEIN DRAFTING COMPRISING IX FACTOR AND HUMAN ALBUMIN FOR THE PROPHYLACTIC TREATMENT OF HEMOPHILIA AND ASSOCIATED METHODS

Publications (2)

Publication Number Publication Date
RU2020103424A RU2020103424A (ru) 2021-07-29
RU2020103424A3 true RU2020103424A3 (enExample) 2021-11-12

Family

ID=62815032

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020103424A RU2020103424A (ru) 2017-06-29 2018-06-29 Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения

Country Status (15)

Country Link
US (1) US20200115436A1 (enExample)
EP (1) EP3645034B1 (enExample)
JP (1) JP2020525498A (enExample)
KR (1) KR102597725B1 (enExample)
CN (1) CN110799209A (enExample)
AU (1) AU2018294517B2 (enExample)
CA (1) CA3068360A1 (enExample)
DK (1) DK3645034T5 (enExample)
ES (1) ES2963665T3 (enExample)
IL (1) IL271160B2 (enExample)
MX (1) MX2019014651A (enExample)
PL (1) PL3645034T3 (enExample)
RU (1) RU2020103424A (enExample)
SG (1) SG10202111032PA (enExample)
WO (1) WO2019002532A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
NZ605348A (en) * 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
TWI810729B (zh) * 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Fix多肽的應用
JP2017502036A (ja) * 2013-12-23 2017-01-19 シーエスエル、リミテッド 血友病の予防的処置のための第ix因子を含む融合タンパク質およびその方法
WO2015154139A1 (en) * 2014-04-11 2015-10-15 Csl Limited Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor

Also Published As

Publication number Publication date
IL271160B1 (en) 2025-01-01
PL3645034T3 (pl) 2024-09-02
AU2018294517B2 (en) 2024-09-26
KR20200019749A (ko) 2020-02-24
AU2018294517A1 (en) 2020-01-30
WO2019002532A1 (en) 2019-01-03
MX2019014651A (es) 2020-02-07
ES2963665T3 (es) 2024-04-01
CA3068360A1 (en) 2019-01-03
US20200115436A1 (en) 2020-04-16
KR102597725B1 (ko) 2023-11-06
IL271160A (en) 2020-01-30
DK3645034T5 (da) 2024-08-26
DK3645034T3 (da) 2023-11-20
JP2020525498A (ja) 2020-08-27
IL271160B2 (en) 2025-05-01
SG10202111032PA (en) 2021-11-29
EP3645034B1 (en) 2023-08-30
EP3645034A1 (en) 2020-05-06
CN110799209A (zh) 2020-02-14
RU2020103424A (ru) 2021-07-29

Similar Documents

Publication Publication Date Title
BR122021024395A2 (enExample)
BR122021000189A2 (enExample)
BR112020006084A8 (enExample)
BR112019008823A2 (enExample)
BR122022025811B8 (enExample)
BR202018014992U2 (enExample)
BR122021023687A2 (enExample)
BR122021014832A2 (enExample)
RU2020103424A3 (enExample)
BR122022003518A2 (enExample)
BR112020008820A2 (enExample)
BR202017025154U2 (enExample)
BR202017021228U2 (enExample)
BE2017C035I2 (enExample)
BR202017011220U2 (enExample)
BR202017010814U2 (enExample)
BR202017010373U2 (enExample)
BR202017009870U2 (enExample)
BR202017006953U2 (enExample)
BR202017004898U2 (enExample)
BR202017002937U2 (enExample)
BR202017002826U2 (enExample)
CN303995159S (enExample)
CN303892650S8 (enExample)
CN304012917S (enExample)